Dublin drug company’s value set to top €280 million in wake of US acquisition

Dublin drug company’s value set to top €280 million in wake of US acquisition
Chief operating officer Rory Nealon

Amryt is raising $60 million from investors in a share sale and last week raised $8 million in a placing as it looks to complete the deal with Aegerion

Amryt, the Dublin-based orphan and rare disease drug firm, will have a market value of more than $300 million (€280 million) after its takeover of the US firm Aegerion.

Amryt is raising $60 million from investors in a share sale and last week raised $8 million in a placing as it looks to complete the deal with Aegerion, which is emerging from bankruptcy protection in the US. The company is also seeking a listing on the US...

Subscribe from just 1€

Exclusive offers

Choose the subscription that is right for you

Monthly Subscription

€1

For the first month

€19.99 Monthly Thereafter

Subscribe today

Cancel anytime

Annual Subscription

€200€149

For the first year

€199.99 annually thereafter

Subscribe today

Cancel anytime

Quarterly Subscription

€55€42

For the first 90 days

€55.00 quarterly Thereafter

Subscribe today

Cancel anytime

These offers are not available for current subscribers. Offers and pricing are subject to change without notice.

Terms & Conditions Apply

Please Subscribe or Log in to continue

Subscribe Login

Related Articles

More from The Business Post